Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Effects of Acceptance and Commitment Care in the Treatment of Aplastic Anemia Patients with Recombinant Human Thrombopoietin.
Psychiatry Clin Psychopharmacol
December 2024
Department of Hematology, Chongqing University Three Gorges Hospital, Chongqing, China.
Background: This study was designed to determine the effects of acceptance and commitment care in the treatment of aplastic anemia (AA) patients with recombinant human thrombopoietin (rhTPO).
Methods: The clinical records of 100 AA patients treated at our hospital from March 2021 to March 2023 were analyzed in the retrospective study. All patients received immunosuppressants and rhTPO.
Assessment of Simplified Surveillance for Congenital Rubella Syndrome in Sudan, 2014-2017.
Vaccines (Basel)
December 2024
Global Immunization Division, United States Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
Background/objectives: Congenital rubella syndrome (CRS) is a constellation of serious multi-organ birth defects following rubella virus infection during early pregnancy. Countries in which rubella vaccination has not yet been introduced can have a high burden of this disease. Data on CRS burden and epidemiology are needed to guide the introduction of a rubella vaccine and monitor progress for rubella elimination, but the multi-system nature of CRS manifestations and required specialized testing creates a challenge for conducting CRS surveillance in developing settings such as Sudan.
View Article and Find Full Text PDFEvaluation of the Efficacy of the Vaccine Production Process in Removing Residual Host Cell DNA from the Vero Cell Rabies Vaccine.
Vaccines (Basel)
December 2024
National Institutes for Food and Drug Control, No. 31, Huatuo Road, Beijing 102629, China.
Background: The Vero cell rabies vaccine is currently the most widely used human rabies vaccine. However, owing to the presence of residual host cell DNA (HCD) in the final product and the potential tumorigenicity of the DNA of high-passage Vero cells, the WHO not only sets a limit on the number of times cells used in production can be passaged, but also imposes strict requirements on the amount of residual HCD in the final vaccine product.
Objectives: To systematically reduce the HCD level in the final vaccine product, multiple purification steps are included in the vaccine production process.
Protective Efficacy of an Inactivated Recombinant Serotype 4 Fowl Adenovirus Against Duck Adenovirus 3 in Muscovy Duck.
Vaccines (Basel)
November 2024
Key Laboratory of Jiangsu Preventive Veterinary Medicine, Key Laboratory for Avian Preventive Medicine, Ministry of Education, College of Veterinary Medicine, Yangzhou University, Yangzhou 225009, China.
Background: Duck adenovirus 3 (DAdV-3) is an emerging pathogen that has caused severe economic losses to the duck industry in China. Recently, the infection of ducks with serotype 4 fowl adenovirus (FAdV-4) has also been reported in China. Therefore, an efficient bivalent vaccine to control the diseases caused by DAdV-3 and FAdV-4 is extremely urgent.
View Article and Find Full Text PDFUAV Trajectory Control and Power Optimization for Low-Latency C-V2X Communications in a Federated Learning Environment.
Sensors (Basel)
December 2024
Department of Electrical, Computer and Biomedical Engineering, Toronto Metropolitan University, Toronto, ON M5B2K3, Canada.
Unmanned aerial vehicle (UAV)-enabled vehicular communications in the sixth generation (6G) are characterized by line-of-sight (LoS) and dynamically varying channel conditions. However, the presence of obstacles in the LoS path leads to shadowed fading environments. In UAV-assisted cellular vehicle-to-everything (C-V2X) communication, vehicle and UAV mobility and shadowing adversely impact latency and throughput.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!